Fas, also known as APO-1 and CD95, is a single-pass, type I transmembrane glycoprotein in the TNF receptor superfamily (TNFRSF6). Fas is highly expressed on epithelial cells, hepatocytes, activated mature lymphocytes, virus­transformed lymphocytes and tumor cells. Fas contains an extracellular domain (ECD) with three cysteine­rich repeats that mediates the interaction with Fas ligand (FasL) or TNFSF6, a type II transmembrane protein expressed on activated T cells, NK cells and other immune cells.  The cytoplasmic region of Fas contains a death domain (DD), which is required for transducing apoptotic signals. Fas is also involved in the activation of NF-κB, ERK, JNK, and alternate pathways for T cell-mediated cytotoxicity. Fas is implicated in the pathogenesis of various malignancies and diseases of the immune system.  Multiple Fas isoforms are derived from alternative splicing. For example, a soluble form that lacks the transmembrane domain is secreted by resting lymphocytes.  Alternate shorter isoforms that lack the DD and have substitutions for cysteine-rich repeats are less prominently expressed. These isoforms can block the extrinsic apoptosis pathway induced by FasL. Fas is an essential mediator in the activation-induced death of T cells that terminates the immune reaction.  In immune-privileged tissues, infiltrating Fas-bearing lymphocytes and inflammatory cells are killed by FasL engagement. Both humans and animals with genetic defects in Fas accumulate abnormal lymphocytes and develop systemic autoimmunity. Mutations in Fas are associated with autoimmune lymphoproliferative syndrome 1A (ALPS1A).

Fas, also known as APO-1 and CD95, is a single-pass, type I transmembrane glycoprotein in the TNF receptor superfamily (TNFRSF6). Fas is highly expressed on epithelial cells, hepatocytes, activated mature lymphocytes, virus­transformed lymphocytes and tumor cells. Fas contains an extracellular domain (ECD) with three cysteine­rich repeats that mediates the interaction with Fas ligand (FasL) or TNFSF6, a type II transmembrane protein expressed on activated T cells, NK cells and other immune cells.  The cytoplasmic region of Fas contains a death domain (DD), which is required for transducing apoptotic signals. Fas is also involved in the activation of NF-κB, ERK, JNK, and alternate pathways for T cell-mediated cytotoxicity. Fas is implicated in the pathogenesis of various malignancies and diseases of the immune system.  Multiple Fas isoforms are derived from alternative splicing. For example, a soluble form that lacks the transmembrane domain is secreted by resting lymphocytes.  Alternate shorter isoforms that lack the DD and have substitutions for cysteine-rich repeats are less prominently expressed. These isoforms can block the extrinsic apoptosis pathway induced by FasL. Fas is an essential mediator in the activation-induced death of T cells that terminates the immune reaction.  In immune-privileged tissues, infiltrating Fas-bearing lymphocytes and inflammatory cells are killed by FasL engagement. Both humans and animals with genetic defects in Fas accumulate abnormal lymphocytes and develop systemic autoimmunity. Mutations in Fas are associated with autoimmune lymphoproliferative syndrome 1A (ALPS1A).

  

Product Details

 

Gene Symbol: TNFRSF6; CD95; APT1; FAS1; APO-1; FASTM; ALPS1A

  

NCBI Gene ID: 355

 

Uniprot Entry: P25445

 

Construct Details: The recombinant human Fas-Fc fusion is expressed as a 376 amino acid protein consisting of Gln26 - Asn173 region of Fas (UniProt accession #P25445) and a C-terminal Fc from human IgG1, which exists as a dimer under non-reducing conditions (see the gel image inserted above). 

   

Source: Human cells stably expressing human Fas-Fc and growing in chemical-defined media with no animal components or antibiotics

 

Deduced Amino Acid Sequence: 

        10         20         30         40         50         60 

QVTDINSKGL ELRKTVTTVE TQNLEGLHHD GQFCHKPCPP GERKARDCTV NGDEPDCVPC  

        70         80         90        100        110        120 

QEGKEYTDKA HFSSKCRRCR LCDEGHGLEV EINCTRTQNT KCRCKPNFFC NSTVCEHCDP  

       130        140        150        160        170        180 

CTKCEHGIIK ECTLTSNTKC KEEGSRSNST GTHTCPPCPA PELLGGPSVF LFPPKPKDTL 

       190        200        210        220        230        240 

MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR VVSVLTVLHQ  

       250        260        270        280        290        300 

DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL PPSREEMTKN QVSLTCLVKG 

       310        320        330        340        350        360 

FYPSDIAVEW ESNGQPENNY KTTPPVLDSD GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA 

       370 

LHNHYTQKSL SLSPGK 

 

M.W.: Calculated molecular mass (kDa): 42.2; Estimated by SDS-PAGE under reducing condition (kDa): 55-60

 

Calculated PI: 6.95

 

Calculated extinction coefficients (M-1 cm-1, at 280nm): 38400

 

Purity: >95% judged by SDS-PAGE under reducing condition (see the gel image above, labeled as "DTT: +")

 

Formulation: Supplied at 0.5 mg/ml in sterile PBS pH7.4 (carrier & preservative free).

 

Endotoxin Level: <0.1 EU per 1 μg of purified recombinant protein determined by the LAL method

 

Biological Activity: Binds to its ligand FasL and inhibits FasL­induced apoptosis in human acute T cell leukemia Jurkat cells.

 

 

  

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Restriction: This product is not transferable or re-sellable.  Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose.  Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules.  Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction.  Your use of this product constitutes acceptance of the terms of this limited use agreement.  Please refer to our “terms & conditions” for details.  If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.

 

Storage

 

The product is shipped at 4°C. Upon receipt, centrifuge the product briefly before opening the vial. It is recommended to store small aliquots at the temperature below –20°C for long-term storage and the product is stable for 3 months. The undiluted protein can be stored at 4°C for no more than 2 weeks.

 

 

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

 

References

 

 

1. Cell. 75: 1169 (1993).

2. Science 263:1759 (1994).

3. J. Immunol. 154: 2706 (1995).

4. Nature. 373: 441 (1995).

5. J. Immunol. 156:4622 (1996).

6. Immunol. Rev. 213:228 (2006).

 

 

 

Documentation

 

Product datasheet (pdf) can be downloaded here: FCL0107-PDS.pdf

 

 

 

Additional supporting documents, including COA and MSDS are available upon request.

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Restriction: This product is not transferable or re-sellable.  Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose.  Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules.  Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction.  Your use of this product constitutes acceptance of the terms of this limited use agreement.  Please refer to our “terms & conditions” for details.  If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.